Biotech Startups

Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.

2 investors

Neurolutions makes IpsiHand, an FDA-cleared brain-computer interface system for at-home motor rehabilitation of chronic stroke survivors with arm and hand weakness. The system pairs a non-invasive EEG headset, a thought-controlled wireless handpiece, and a tablet to guide and track therapy.

2 investors

Neuromorphic develops hardware-agnostic control software for robots, letting operators deploy and manage them through everyday interfaces such as Slack, email, and phone. It targets wet labs and other physical industries that want to add robots with minimal setup.

2 investors

NeuWave Medical develops the NeuWave Microwave Ablation System, a device used by healthcare professionals to ablate soft tissue, including non-resectable liver tumors, in percutaneous, open surgical, and laparoscopic settings. The system includes a probe portfolio and ABLATE-IQ software for margin confirmation, and is marketed for use in the United States; the company is a wholly owned subsidiary of Quantum Surgical, Inc.

2 investors

2 investors

New Culture makes animal-free dairy cheese using precision fermentation and food science, starting with mozzarella aimed first at pizzerias. Its products are lactose-free and designed to melt, stretch, and taste like conventional cheese without using cows.

2 investors

2 investors

Shanghai NewMed Medical is a Chinese medical device company founded in 2015 that develops, manufactures, and sells transcatheter artificial heart valves and interventional ventricular assist systems. Its products target interventional treatment of cardiovascular disease for clinicians and patients in China.

2 investors

New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.

2 investors

NexCure partners with health systems to build and operate outpatient treatment centers focused on delivering advanced cancer therapies such as CAR-T and T-cell engagers. Its platform combines AI-powered patient selection, remote monitoring, and standardized clinical protocols to bring these treatments to patients in outpatient settings across the country.

2 investors

NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).

2 investors

NexMR, an ETH Zurich spin-off, develops light-coupled NMR hardware, consumables, and automated analysis software to increase throughput and reduce resource use in NMR-based drug discovery pipelines. Its sensitivity-enhanced technology targets early-stage drug discovery workflows, including hit affinity determination and screening of challenging targets.

2 investors

Nextmol (Bytelab Solutions SL) is a computational chemistry company that develops molecular modeling and AI tools, offered both as services and via a SaaS platform, to accelerate the design of more sustainable chemicals for the chemical industry. A spin-off of the Barcelona Supercomputing Center, its work focuses on generative AI for molecular design, property prediction, and chemical space exploration for applications such as polymers and surfactants.

2 investors

nference transforms unstructured biomedical data from electronic medical records into technological solutions that enable scientific discovery of diagnostics and treatments. The company partners with medical centers to synthesize healthcare data for personalized medicine research.

2 investors

NFlection is a biopharmaceutical company developing novel therapeutics. The page does not state what the company's specific products or therapeutic focus are.

2 investors

NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway. Its current programs target hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia, both in Phase 2 clinical trials.

2 investors

NGM Biopharmaceuticals is a clinical-stage biotech developing biologic drugs for cardio-metabolic, liver, oncology, and pregnancy-related conditions based on proprietary disease pathway research.

2 investors

Niacet produces anhydrous hydrogen chloride and hydrochloric acid at ultra-high purity grades for use in pharmaceutical, chemical, and electronics industries. The company specializes in electronics-grade products at 99.999% purity and technical-grade variants, along with hydrochloric acid solutions at various concentrations.

2 investors

Nibec is a South Korean biotech company that develops peptide-based therapeutics and dental biomaterials, including bone graft materials, periodontal tissue regeneration products, tooth-whitening agents, and drug-delivery platforms. It supplies materials to global implant and pharmaceutical companies and pursues clinical development of treatments for conditions such as pulmonary fibrosis and inflammatory bowel disease.

2 investors

Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.

2 investors

A biopharmaceutical company that discovers and develops medicines, building on immunology research to explore additional disease areas. The page content appears to redirect to AbbVie, and provides limited specific information about Nimble Therapeutics itself.

2 investors

Nirvana Sciences develops dyes, probes, and contrast agents for life science applications, including organic dyes with narrow emission profiles and a library of over 700 chlorin and bacteriochlorin designs. Its products target life science research and imaging uses.

2 investors

NKA Bio develops antibody-based medicines for critically ill and trauma patients to extend survival time during medical emergencies. The company's lead candidate, NKA01, is an anti-shock toxin antibody administered by emergency medical services to stabilize trauma patients and buy time for transport and surgical intervention.

2 investors

Nob Hill Therapeutics develops inhalation medicines and delivery technologies for high-dose delivery of drugs to the lungs. It aims to create new therapies for lung-related diseases that are currently difficult to treat.

2 investors